Rahmer Peter 4

What Happened Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics (RLAY), sold 50,000 shares on June 30, 2026 in an open-market/private sale for a weighted average price of $19.09, totaling approximately $954,500. On the same date he acquired 3,056 shares under the company's 2020 Employee Stock Purchase Plan (ESPP) at $6.95 per share for about $21,239. The sale was a disposition (often routine), while the ESPP purchase is a direct buy by the insider.

Key Details

• Transaction date(s): June 30, 2026.
• Sale: 50,000 shares sold at a weighted average price of $19.09 (trade prices ranged $18.66–$19.78); total proceeds ~$954,500.
• Purchase: 3,056 shares acquired under ESPP at $6.95 per share; total cost ~$21,239.
• Shares owned after transaction: the excerpt does not state total beneficial ownership; filing notes holdings include 9,153 shares underlying restricted stock units (RSUs).
• Notable footnotes:
  • Sale executed pursuant to a pre-established Rule 10b5-1 trading plan adopted Oct 31, 2025.
  • Seller will provide, upon request, a breakdown of the multiple trade prices within the $18.66–$19.78 range.
  • ESPP purchase was exempt under Rule 16b-3 and was purchased at 85% of the Jan 2, 2026 closing price (voluntarily reported).
• Filing timeliness: Report filed July 2, 2026 for a June 30 transaction — appears timely.

Context A sale executed under a 10b5-1 plan is generally pre-scheduled and is commonly seen in insider Form 4s; it doesn't necessarily signal a change in insider view. The ESPP purchase is a direct insider buy and is typically viewed as a straightforward acquisition of company shares. This filing is factual disclosure of both a sizable sale and a small ESPP purchase; it does not reveal the insider's motives.